Accelr8 Faces Delisting from NYSE Alternext | GenomeWeb

NEW YORK (GenomeWeb News) — Accelr8 said today that it has received notice from the NYSE Alternext that it is not in compliance with certain listing standards concerning its amount of stockholder equity, and that it must submit and implement a plan to regain compliance within 18 months.

The company said it is not in compliance with a section of the NYSE Alternext’s listing standards because it holds stockholder equity of less than $6 million and it has had losses from continuing operations and net losses in its five most recent fiscal years.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.